The research team, led by investigators affiliated with Nanchang University, began by asking a deceptively simple question: do ovarian tumours harbour fungi, and if so, does the fungal community differ between benign borderline tumours and full-blown epithelial ovarian cancer? To answer it, they recruited 40 women aged 18 to 75, half with epithelial ovarian cancer (EOC) and half with epithelial borderline ovarian tumours (EBOT), a precursor-like condition that lacks destructive stromal invasion. Tissue was collected under strictly sterile conditions during surgery, snap-frozen in glycerol preservation solution, and subjected to sequencing of the internal transcribed spacer 1 (ITS1) region of fungal ribosomal DNA, the standard barcoding tool for fungal community profiling.

The results were striking. Fluorescence in situ hybridisation using a pan-fungal probe targeting 28S rRNA confirmed that fungal signals were present in both tumour types, but the signals were markedly stronger in the malignant tissue. Sequencing revealed that EOC samples had significantly reduced fungal alpha-diversity, with lower Chao1 indices and fewer observed species, alongside clear separation in beta-diversity clustering. At the genus level, the malignant tumours were significantly enriched in Malassezia and Meyerozyma, while Cutaneotrichosporon was depleted. Quantitative PCR validated the Malassezia enrichment, and, perhaps most provocatively, the abundance of the genus correlated positively with serum CA125, the clinical biomarker used to track ovarian cancer burden. The implication was hard to escape: the more aggressive the disease, the more Malassezia was present.

Correlation, of course, is not causation, and this is where the study distinguishes itself from the many catalogue-style microbiome papers that have accumulated in recent years. To test whether the tumour-associated fungi were doing anything, the team transplanted microbial communities extracted from patient tissues directly into established tumours in a murine model of EOC, using subcutaneously implanted ID8 ovarian cancer cells in C57BL/6 mice. Before transplantation, mice were depleted of their endogenous fungi with amphotericin B, delivered by gavage and in drinking water, to create a clean experimental backdrop.

The outcome was unambiguous. Both EBOT-derived and EOC-derived microbiota accelerated tumour growth, but the EOC-derived communities were markedly more potent. Tumours in the transplant groups grew faster, weighed more, and showed denser populations of atypical neoplastic cells, along with a higher proportion of Ki-67-positive proliferating cells on immunohistochemistry. Critically, body weights remained stable across all groups, suggesting the effect was localised to the tumour microenvironment rather than a systemic toxic effect. The fungal-depleted mice without transplants grew tumours at rates indistinguishable from controls, ruling out amphotericin B itself as a confounder.

With the transplantation model established, the researchers narrowed their focus to Malassezia restricta, one of the most prevalent fungal species previously identified across diverse human tumours. Injecting M. restricta alone directly into tumours reproduced the pro-tumour phenotype almost exactly, matching the effect of the full EOC-derived microbial community. This single fungal species, it turned out, carried most of the tumour-promoting punch.

But how does a yeast manipulate a tumour from within? The team turned to the immune landscape of the tumours, characterising macrophage subsets by immunofluorescence, quantitative PCR, western blot and ELISA. Macrophages in tumours are notoriously plastic, existing along a spectrum from classically activated M1 cells, which produce inflammatory cytokines like TNF-α and IL-6 and fight tumours, to alternatively activated M2 cells, which secrete immunosuppressive IL-10 and TGF-β and express markers such as CD206 and arginase-1 (Arg1). In the M. restricta-colonised tumours, the balance tipped decisively toward M2: CD206-positive cells infiltrated in far greater numbers, CD206 and Arg1 transcripts surged, Arg1 protein rose, and IL-10 and TGF-β climbed. M1 markers, CD4-positive and CD8-positive T-cell populations all remained essentially unchanged. The fungus, in other words, was not broadly perturbing immunity but performing a precise surgical reprogramming of the macrophage compartment.

The search for the molecular mediator led to extracellular vesicles, nanoscale bilayer-membrane particles that microbes and host cells alike use as intercellular couriers, ferrying proteins, nucleic acids, lipids and metabolites between cells. When the researchers grew M. restricta in culture and separated its supernatant from its heat-killed cell bodies, only the supernatant induced M2 polarisation in RAW264.7 macrophages, pointing toward a soluble, secreted effector. Ultracentrifugation of the supernatant at 100,000 × g yielded a purified vesicle fraction. Transmission electron microscopy revealed the classic cup-shaped morphology of extracellular vesicles, and nanoparticle tracking analysis placed their diameter between 50 and 300 nanometres, averaging 154.8 nanometres. Labelling the vesicles with the fluorescent dye PKH26 showed that macrophages avidly internalised them within 24 hours, with the vesicles accumulating in the perinuclear region.

Once inside, the vesicles got to work. Treating macrophages with the purified M. restricta extracellular vesicles (MrEVs) at 20 micrograms per millilitre reproduced the full M2 signature: elevated CD206 and Arg1, increased IL-10 and TGF-β secretion, and the phenotypic shift confirmed by multiple independent assays. Screening candidate signalling pathways revealed that the vesicles selectively upregulated TLR4, the Toll-like receptor 4 that serves as a key sensor of microbial ligands, and JAK2, the Janus kinase at the head of one of the most consequential inflammatory cascades in immunology. Western blotting confirmed the downstream consequences: increased phosphorylation of both JAK2 and its transcription factor target STAT3, the canonical molecular switch that drives macrophages toward the M2 fate.

The mechanistic proof came through pharmacological inhibition. AG490, a selective JAK2 inhibitor, was applied both to MrEV-treated macrophages in vitro and to M. restricta-colonised mice in vivo. In the cell experiments, AG490 suppressed the vesicle-induced phosphorylation of JAK2 and STAT3, prevented the rise in CD206 and Arg1, blocked IL-10 and TGF-β secretion, and critically, eliminated the ability of MrEV-conditioned macrophages to stimulate the proliferation and migration of ID8 ovarian cancer cells in wound-healing and CCK-8 assays. In the mice, AG490 administration alongside M. restricta colonisation shrank tumours, reduced Ki-67 staining, blocked CD206-positive M2 infiltration and dampened Arg1 and JAK2/STAT3 phosphorylation in the tumour tissue. The pathway, in short, was both necessary and sufficient for the fungal effect.

The significance of this work extends well beyond ovarian cancer. Over the past several years, the intratumoural microbiome has transitioned from a contested idea to an established field, with bacterial communities documented in pancreatic, breast, lung and colorectal malignancies, and fungal communities mapped across 35 cancer types. Earlier studies had already implicated Malassezia in other cancers: M. globosa accumulation in breast tumours drives IL-17A-dependent M2 polarisation, and Malassezia enrichment in hepatocellular carcinoma correlates with poor prognosis by reshaping bile acid metabolism. But the present study is among the first to trace a complete causal chain in ovarian cancer, from fungal presence in patient tissue, through transplantation and mono-colonisation in living animals, to a defined molecular effector, a defined receptor-pathway axis, and a pharmacological rescue.

It also opens a genuinely new therapeutic door. The JAK2/STAT3 pathway is already druggable, with inhibitors in clinical use for myelofibrosis and under investigation across oncology, and the tumour-associated macrophage phenotype it controls is a validated target of immuno-oncology programs worldwide. If M. restricta enrichment and its vesicle-mediated signalling can be confirmed in larger patient cohorts, measures of intratumoural fungal load might serve as biomarkers for selecting patients likely to benefit from JAK-pathway modulation or macrophage-reprogramming strategies. Conversely, interventions that displace or suppress pro-tumourigenic fungi, as amphotericin B did in the mouse model, could complement existing treatments, though the authors caution that much work remains.

Limitations deserve honest mention. The clinical cohort was modest, 20 patients per group, and the colonisation burden of Malassezia was not quantitatively measured with digital PCR or metagenomic tools. Germ-free mouse models would eliminate residual confounding from endogenous fungi, and the specific molecular cargo within MrEVs that engages TLR4 remains unidentified. The authors suggest proteomic and small RNA sequencing approaches to pinpoint these ligands, and note that complete JAK2 knockout models would strengthen the pathway validation beyond what AG490’s partial inhibition can achieve.

Still, the central message stands. A fungus best known for contributing to dandruff and seborrheic dermatitis has been shown, through a rigorous chain of patient sequencing, animal transplantation, vesicle purification and pathway rescue, to help ovarian cancer grow by hijacking the very immune cells meant to fight it. It is a vivid reminder that tumours are not merely masses of mutated cells but complex ecosystems, and that within those ecosystems, even the smallest and most overlooked inhabitants may hold the keys to new diagnostics and new cures. The fungal-immune axis in cancer, once invisible, is now in plain sight, and it is unlikely to be ignored again.

Traditional vaccine adjuvants, which serve to boost the immune system’s reaction to pathogens, generally produce transient effects, offering a limited window during which immune activation occurs. In contrast, the newly developed method leverages mRNA technology to reprogram immune cells intrinsically. Rather than merely stimulating immune cells externally, this technique delivers mRNA molecules encoding two pivotal immune-related genes, IRF8 (Interferon Regulatory Factor 8) and NIK (NF-kappa-B-inducing kinase), directly into the target cells. These genes orchestrate critical intracellular signaling cascades that enhance the functionality and persistence of immune effector cells.

The heart of this innovation lies in the capacity of this mRNA-based adjuvant to modify dendritic cells, which are essential for antigen presentation and T-cell activation. By increasing the activity of these sentinel cells within the immune system, the approach ensures a more robust and prolonged engagement of T cells, especially cytotoxic T lymphocytes that can identify and eliminate infected or malignant cells. This mechanistic insight translates into a durable antitumor response, as evidenced by extensive mouse model studies.

Akash Gupta, the lead author and Presidential Frontier Faculty Fellow at the University of Houston, emphasizes the profound impact observed in preclinical investigations. He describes how the mRNA-encoded adjuvant led to the complete eradication of tumors in various cancer models, either as a standalone treatment or when combined with tumor-specific antigens. Furthermore, the same methodology significantly intensified T-cell responses to vaccines formulated against prevalent viral infections, pointing to broad applicability across diverse disease contexts.

A distinctive feature of this strategy is its ability to integrate seamlessly with existing vaccine platforms. The researchers demonstrated that co-administration of the mRNA adjuvant with influenza and COVID-19 vaccines resulted in a 10- to 15-fold increase in antigen-specific T-cell populations. This finding suggests potential for dramatically improving vaccine efficacy, especially in populations where immune responses tend to be suboptimal, such as the elderly or immunocompromised individuals.

Daniel Anderson, a senior author and professor of Chemical Engineering at MIT, highlights the novelty of the approach, noting that while most cancer immunotherapies rely on extrinsic signals to provoke immune activation, this technique reprograms the immune cells intracellularly. By directly manipulating the signaling machinery within dendritic cells, the method promotes sustained immune surveillance and potentiates the cytotoxic functions of T cells.

Extending beyond cancer therapy and infectious diseases, the novel mRNA delivery system could serve as a versatile platform for immunomodulation. The dual expression of IRF8 and NIK coordinates the activation of multiple immune pathways. IRF8 is instrumental in dendritic cell differentiation and type I interferon responses, while NIK governs non-canonical NF-kB signaling, a pathway critical for immune cell survival and maturation. The confluence of these pathways offers a comprehensive and durable immune remodeling effect.

Investigators, including co-first author Riddha Das, are exploring the potential synergistic effects of this mRNA adjuvant when combined with checkpoint inhibitor therapies, which have revolutionized cancer treatment by unleashing T cells from inhibitory signals. Early data reveal that this combination substantially enhances therapeutic outcomes, potentially overcoming resistance mechanisms and improving patient prognosis in recalcitrant tumors.

Importantly, the safety profile of this mRNA-based adjuvant remains a critical aspect under development. Given the extensive use of mRNA vaccines during the COVID-19 pandemic, there is growing confidence in the tolerability and scalability of mRNA delivery systems. The researchers aim to expand preclinical studies to more advanced cancer models and initiate clinician-directed translational studies to assess safety, dosing, and efficacy in human subjects.

This breakthrough underscores the rapidly advancing frontier of mRNA technology beyond its initial application in infectious disease vaccines. By reengineering immune cells at a molecular level, the approach opens new avenues for durable immune memory formation and robust antitumor immunity. It also paves the way for next-generation vaccine design that not only prevents infections more effectively but could also potentially eradicate established cancers.

Funding for this research was provided by a coalition of prestigious institutions and organizations, including Sanofi, the National Institutes of Health, the Marble Center for Cancer Nanomedicine, and the National Cancer Institute’s Koch Institute Support Grant. Such support reflects the high translational potential and clinical significance of this innovative immunotherapy platform.

Looking ahead, the research team plans to deepen mechanistic understanding and optimize delivery systems to maximize therapeutic efficacy. With the increasing global urgency for effective cancer treatments and pandemic preparedness, this mRNA-based immune remodeling strategy represents a beacon of hope, marrying cutting-edge molecular engineering with immune biology to usher in a new era in medicine.

Subject of Research: mRNA-based immune remodeling strategy to amplify T-cell response for cancer immunotherapy and infectious disease vaccines

Article Title: Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models

News Publication Date: 13-May-2026

Web References:
https://www.nature.com/articles/s41587-026-03115-2

Image Credits: University of Houston

Keywords: mRNA technology, T-cell response, cancer immunotherapy, vaccine adjuvant, IRF8, NIK, dendritic cells, immune remodeling, infectious disease vaccines, COVID-19, influenza, checkpoint inhibitors